Chiropractors and acupuncturists who have lobbied for a bigger role in treating pain have won a preliminary endorsement from federal health officials.
The Food and Drug Administration released proposed changes Wednesday to its blueprint on educating health care providers about treating pain. The guidelines now recommend that doctors get information about chiropractic care and acupuncture as therapies that might help patients avoid prescription opioids.
“[Health care providers] should be knowledgeable about the range of available therapies, when they may be helpful, and when they should be used as part of a multidisciplinary approach to pain management,” the agency wrote in the proposal.
The suggested changes come as chiropractors and other alternative medicine providers have stepped up lobbying Congress and state legislatures to elevate their role in treating chronic pain. They’ve scored several big victories in recent years.
In Oregon, the state Medicaid program decided to cover chiropractic care for lower back pain starting in 2016. Other states are considering similar moves. And earlier this year, the chiropractic industry cheered when the American College of Physicians recommended non-surgical treatments such as acupuncture, yoga, and chiropractic care as the first options for treating lower back pain.
The FDA’s draft blueprint isn’t final — and drug makers, doctors, and alternative medicine providers will all have a chance to weigh in. The FDA will take public comments through July 10.
The blueprint released this week is part of a strategy the FDA rolled out in 2011 to address a crisis of prescription drug abuse. The FDA required opioid manufacturers to provide education for health providers who prescribe their pain medications — but didn’t mention chiropractic care or acupuncture in its initial blueprint for what that education ought to look like.
Now, the agency is seeking to give prescribers more information on a broader range of approaches to manage pain, including non-pharmacologic therapies, said Sarah Peddicord, a spokesperson for the FDA.